Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SLx-2101

Other · developed by Retension Pharmaceuticals.

Phase 2 Most advanced trial (none active)
RTSN Developer
1 Registered trials

What is SLx-2101?

SLx-2101 is a drug studied in hypertension.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Cardiovascular
Developer
Retension Pharmaceuticals. Inc. (RTSN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00562549 Phase 2 Hypertension Completed RTSN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hypertension

More from Retension Pharmaceuticals.

Follow RTSN, the company behind SLx-2101

See RTSN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RTSN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.